The Company enters into research, development and license agreements in the ordinary course of business where the Company receives research services and rights to proprietary technologies. Milestone and royalty payments that become due under various agreements are dependent on, among other factors, clinical trials, regulatory approvals and ultimately the successful development of a new drug, the outcome and timing of which is uncertain.

 

Under the Company's license agreement with CrystalGenomics for rights to CG- in all territories outside of the Republic of Korea and China, the Company has obligations for development milestones of million related to the initiation of Phase and pivotal clinical trials, and regulatory milestones totaling million. The Company also has an obligation to pay royalty payments on sales of commercialized product. The timing of any milestone or royalty payments that become due is yet determinable.

 

On the Company entered into a license agreement with CrystalGenomics to gain an exclusive license to CG- in China. The Company has potential future obligations of development milestones of million related to approval of an Investigational New Drug (“IND”) and to the initiation of Phase and pivotal clinical trials, and regulatory milestones totaling million. The Company also has an obligation to pay sales milestones and royalty payments on sales of commercialized product. The timing or likelihood of any milestone or royalty payments that become due is yet determinable.

 

On we entered into an exclusive global license agreement with Ohm Oncology (OHM), for the development, manufacture and commercialization of APL- as well as related molecules from our dual bromodomain and extra-terminal domain motif (BET) protein and kinase inhibitor program. Under the agreement, we will retain reacquisition rights to certain molecules, while OHM/LALS will have the rights to develop and sublicense all other molecules. We have received nominal upfront cash payments and are eligible to receive up to million of additional payments based on the achievement of certain development, regulatory and sales milestones, as well as significant royalties on future sales generated from the program, if any.